Regulatory Modernization in Brazil: ANVISA’s Path Toward Traceability and Agility in 2026
The Brazilian regulatory landscape in 2026 solidifies the transition to a fully digital environment. With the mandatory implementation of Unique Device Identification (UDI) and new rules for electronic prescriptions, ANVISA focuses on patient safety and the de-bureaucratization of processes.